← Leaderboards
Samuel E Gandy
Rockefeller University
$18,006,077
Attributed
$48,372,858
Total exposure
22
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $7.1M · FY2005–22$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$59,436,133 · 20
VA$0 · 3
By mechanism
U01$25,534,922 · 1
P01$12,672,519 · 5
RF1$8,813,342 · 3
R01$8,374,495 · 6
R56$1,702,364 · 2
P50$1,324,377 · 1
Top collaborators
- Scott Allen Noggle25 shared
- Michelle E Ehrlich23 shared
- Vahram Haroutunian20 shared
- Eric E Schadt20 shared
- Bin Zhang20 shared
- Koichi Iijima11 shared
- Jun Zhu11 shared
- Valentina Fossati5 shared
Most similar at Rockefeller University
Same institution · by research overlap
- Gunnar K Gouras$3,063,475
- Angus C. Nairn$15,314,298
- Hong Wang$127,972
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposS DiseaseBrainCellsNeuronsMolecularPathologyBaseProteinsGenesGeneticAmyloid Beta-ProteinMouse ModelStructureComplexBiologyPhenotypeBrain CellCell Culture TechniquesValidationInduced Pluripotent Stem CellCell TypeS Disease ModelVariant
Grant awards (87)
Integrative Network Biology Approaches to Identify, Characterize and Validate Molecular Subtypes in Alzheimer's Disease$2,272,422
U01 · FY2022 · AG
Use of iPSC systems to define roles of microglial TREM2/DAP12 and CR3/DAP12 complexes and their genetic variants in specifying risk for late onset sporadic Alzheimer's disease$877,246
R01 · FY2022 · AG
Integrative Network Biology Approaches to Identify, Characterize and Validate Molecular Subtypes in Alzheimer's Disease$1,848,040
U01 · FY2021 · AG
Use of iPSC systems to define roles of microglial TREM2/DAP12 and CR3/DAP12 complexes and their genetic variants in specifying risk for late onset sporadic Alzheimer's disease$877,246
R01 · FY2021 · AG
Identification and characterization of receptors targeting VGF-derived peptides.$169,500
U01 · FY2021 · AG
Proneurogenic Treatment for Amyloid or Tau-Based Neurodegeneration$0
I01 · FY2021 · VA · contact PI
Integrative Network Biology Approaches to Identify, Characterize and Validate Molecular Subtypes in Alzheimer's Disease$3,115,604
U01 · FY2020 · AG
Integrative Network Biology Approaches to Identify, Characterize and Validate Molecular Subtypes in Alzheimer's Disease$1,265,373
U01 · FY2020 · AG
Use of iPSC systems to define roles of microglial TREM2/DAP12 and CR3/DAP12 complexes and their genetic variants in specifying risk for late onset sporadic Alzheimer's disease$877,246
R01 · FY2020 · AG
Deciphering the enigmatic role of IGF-1 signaling in cognitive decline and Alzheimer's disease$858,252
R56 · FY2020 · AG
Integrative Network Biology Approaches to Identify, Characterize and Validate Molecular Subtypes in Alzheimer's Disease$164,076
U01 · FY2020 · AG
Proneurogenic Treatment for Amyloid or Tau-Based Neurodegeneration$0
I01 · FY2020 · VA · contact PI
Integrated understanding of complex viral network biology in Alzheimer's Disease$4,111,077
RF1 · FY2019 · AG
Integrative Network Biology Approaches to Identify, Characterize and Validate Molecular Subtypes in Alzheimer's Disease$1,691,295
U01 · FY2019 · AG
Use of iPSC systems to define roles of microglial TREM2/DAP12 and CR3/DAP12 complexes and their genetic variants in specifying risk for late onset sporadic Alzheimer's disease$877,246
R01 · FY2019 · AG
Integrative Network Biology Approaches to Identify, Characterize and Validate Molecular Subtypes in Alzheimer's Disease$423,750
U01 · FY2019 · AG
Proneurogenic Treatment for Amyloid or Tau-Based Neurodegeneration$0
I01 · FY2019 · VA · contact PI
SYSTEMATIC DRUG REPURPOSING TARGETING IMMUNE ACTIVATION NETWORKS IN ALZHEIMER'S DISEASE (AD)$4,186,456
RF1 · FY2018 · AG · contact PI
Integrative Network Biology Approaches to Identify, Characterize and Validate Molecular Subtypes in Alzheimer's Disease$1,708,836
U01 · FY2018 · AG
Use of iPSC systems to define roles of microglial TREM2/DAP12 and CR3/DAP12 complexes and their genetic variants in specifying risk for late onset sporadic Alzheimer's disease$641,748
R01 · FY2018 · AG
Proneurogenic Treatment for Amyloid or Tau-Based Neurodegeneration$0
I01 · FY2018 · VA · contact PI
Integrative Biology Approach to Complexity of Alzheimer's Disease$2,699,009
U01 · FY2017 · AG
Integrated understanding of complex viral network biology in Alzheimer's Disease$844,112
R56 · FY2017 · AG
Integrative Biology Approach to Complexity of Alzheimer's Disease$169,498
U01 · FY2017 · AG
Rehab Therapy Adjunct with a Neurogenic, Mnemoactive, A-Beta-Lowering Compound$0
I01 · FY2017 · VA · contact PI
Proneurogenic Treatment for Amyloid or Tau-Based Neurodegeneration$0
I01 · FY2017 · VA · contact PI
Integrative Biology Approach to Complexity of Alzheimer's Disease$3,281,179
U01 · FY2016 · AG
Integrative Biology Approach to Complexity of Alzheimer's Disease$1,139,520
U01 · FY2016 · AG
Integrative Biology Approach to Complexity of Alzheimer's Disease$168,108
U01 · FY2016 · AG
Rehab Therapy Adjunct with a Neurogenic, Mnemoactive, A-Beta-Lowering Compound$0
I01 · FY2016 · VA · contact PI
Integrative Biology Approach to Complexity of Alzheimer's Disease$1,702,824
U01 · FY2015 · AG
Model for SorCS1-mediated Diabetes with Dementia$370,781
R01 · FY2015 · NS · contact PI
Integrative Biology Approach to Complexity of Alzheimer's Disease$111,000
U01 · FY2015 · AG
Integrative Biology Approach to Complexity of Alzheimer's Disease$96,335
U01 · FY2015 · AG
Rehab Therapy Adjunct with a Neurogenic, Mnemoactive, A-Beta-Lowering Compound$0
I01 · FY2015 · VA · contact PI
Integrative Biology Approach to Complexity of Alzheimer's Disease$1,734,746
U01 · FY2014 · AG
Model for SorCS1-mediated Diabetes with Dementia$367,074
R01 · FY2014 · NS · contact PI
Network Based Predictive Drug Discovery for Alzheimer's Disease$366,497
R34 · FY2014 · AG
EVIDENCE FOR GAMMA-SECRETASE DYSFUNCTION IN SPORADIC AD$243,752
P50 · FY2014 · AG · contact PI
Phase 11-Grape Seed Extract as Anti-Oligomerization Agent in Alzheimer's Disease$164,415
R21 · FY2014 · AT · contact PI
Accelerating Medicine Partnership in Alzheimer's Disease: Enabling collaborative$114,059
U01 · FY2014 · AG
Rehab Therapy Adjunct with a Neurogenic, Mnemoactive, A-Beta-Lowering Compound$0
I01 · FY2014 · VA · contact PI
Integrative Biology Approach to Complexity of Alzheimer's Disease$1,659,748
U01 · FY2013 · AG
Model for SorCS1-mediated Diabetes with Dementia$357,804
R01 · FY2013 · NS · contact PI
EVIDENCE FOR GAMMA-SECRETASE DYSFUNCTION IN SPORADIC AD$249,327
P50 · FY2013 · AG · contact PI
Generation and Characterization of Alzheimer Brain Cells$515,809
RF1 · FY2012 · AG · contact PI
Model for SorCS1-mediated Diabetes with Dementia$370,781
R01 · FY2012 · NS · contact PI
EVIDENCE FOR GAMMA-SECRETASE DYSFUNCTION IN SPORADIC AD$293,871
P50 · FY2012 · AG · contact PI
Phase 11-Grape Seed Extract as Anti-Oligomerization Agent in Alzheimer's Disease$241,601
R21 · FY2012 · AT · contact PI
Alzheimer Mouse Model for Intraneuronal Amyloid-Beta Oligomer Biology$0
I01 · FY2012 · VA · contact PI
EVIDENCE FOR GAMMA-SECRETASE DYSFUNCTION IN SPORADIC AD$283,351
P50 · FY2011 · AG · contact PI
Alzheimer Mouse Model for Intraneuronal Amyloid-Beta Oligomer Biology$0
I01 · FY2011 · VA · contact PI
EVIDENCE FOR GAMMA-SECRETASE DYSFUNCTION IN SPORADIC AD$254,076
P50 · FY2010 · AG · contact PI
Phase 11-Grape Seed Extract as Anti-Oligomerization Agent in Alzheimer's Disease$241,601
R21 · FY2010 · AT · contact PI
Interdisciplinary Approach to Alzheimer Drug Discovery$1,396,412
P01 · FY2009 · AG · contact PI
LIPOPROTEINS, SIGNAL TRANSDUCTION, AND ACTIVATION OF APP ECTODOMAIN SHEDDING$279,282
P01 · FY2009 · AG · contact PI
Alzheimer Mouse Model for Intraneuronal Amyloid-Beta Oligomer Biology$0
I01 · FY2009 · VA · contact PI
Interdisciplinary Approach to Alzheimer Drug Discovery$1,535,008
P01 · FY2008 · AG · contact PI
LIPOPROTEINS, SIGNAL TRANSDUCTION, AND ACTIVATION OF APP ECTODOMAIN SHEDDING$307,002
P01 · FY2008 · AG · contact PI
Interdisciplinary Approach to Alzheimer Drug Discovery$1,554,521
P01 · FY2007 · AG · contact PI
PRESENILIN DOMAINS AND RECONSTITUTION OF CATALYSIS$329,471
R01 · FY2007 · AG · contact PI
LIPOPROTEINS, SIGNAL TRANSDUCTION, AND ACTIVATION OF APP ECTODOMAIN SHEDDING$310,904
P01 · FY2007 · AG · contact PI
Interdisciplinary Approach to Alzheimer Drug Discovery$1,917,793
P01 · FY2006 · AG · contact PI
PRESENILIN DOMAINS AND RECONSTITUTION OF CATALYSIS$274,611
R01 · FY2006 · AG · contact PI
LIPOPROTEINS, SIGNAL TRANSDUCTION, ACTIVATION OF APP ECT$222,223
P01 · FY2006 · AG · contact PI
Interdisciplinary Approach to Alzheimer Drug Discovery$1,099,042
P01 · FY2005 · AG
PRESENILIN DOMAINS AND RECONSTITUTION OF CATALYSIS$294,085
R01 · FY2005 · AG
LIPOPROTEINS, SIGNAL TRANSDUCTION, ACTIVATION OF APP ECT$124,128
P01 · FY2005 · AG
ADMINISTRATIVE CORE$124,125
P01 · FY2005 · AG
ESTROGEN MODULATION OF BRAIN ABETA METABOLISM IN VIVO$307,079
R01 · FY2004 · NS
INTERDISCIPLINARY APPROACH TO ALZHEIMER DRUG DISCOVERY$905,450
P01 · FY2003 · AG
ESTROGEN MODULATION OF BRAIN ABETA METABOLISM IN VIVO$235,500
R01 · FY2003 · NS
ESTROGEN MODULATION OF BRAIN ABETA METABOLISM IN VIVO$71,579
R01 · FY2003 · NS
INTERDISCIPLINARY APPROACH TO ALZHEIMER DRUG DISCOVERY$921,845
P01 · FY2002 · AG
TRANSMITTER NEUROANATOMY IN ALZHEIMERS DISEASE$329,167
R01 · FY2002 · AG
BABAA RECEPTORS IN AGING &ALZHEIMER'S DISEASE$283,781
R01 · FY2002 · AG
ESTROGEN MODULATION OF BRAIN ABETA METABOLISM IN VIVO$240,000
R01 · FY2002 · NS
ESTROGEN MODULATION OF BRAIN ABETA METABOLISM IN VIVO$62,800
R01 · FY2002 · NS
ESTROGEN MODULATION OF BRAIN ABETA METABOLISM IN VIVO$7,500
R01 · FY2002 · NS
Protein protein interactions in Amyloid Beta metabolism$0
P01 · FY2002 · AG
INTERDISCIPLINARY APPROACH TO ALZHEIMER DRUG DISCOVERY$844,145
P01 · FY2001 · AG
ESTROGEN MODULATION OF BRAIN ABETA METABOLISM IN VIVO$247,500
R01 · FY2001 · NS
ESTROGEN MODULATION OF BRAIN ABETA METABOLISM IN VIVO$74,250
R01 · FY2001 · NS
Protein protein interactions in Amyloid Beta metabolism$0
P01 · FY2001 · AG
INTERDISCIPLINARY APPROACH TO ALZHEIMER DRUG DISCOVERY$889,059
P01 · FY2000 · AG
CELL BIOLOGICAL STUDIES OF AMYLOID PRECURSOR PROTEIN$241,580
P01 · FY2000 · AG
Protein protein interactions in Amyloid Beta metabolism$0
P01 · FY2000 · AG